Smoking CessationPhase 4NCT06474299
The Avenues Study: Dual Use Cessation
A Phase 4 study testing Varenicline, Nicotine patch and Dual Focused Cessation Counseling in people with Smoking Cessation and Electronic Cigarette Use, run by University of Wisconsin, Madison at 1 site in United States.
Trial summary
The overarching goal of this research is to determine the most effective approach for helping dual users of cigarettes and electronic nicotine delivery systems (ENDS) quit smoking. 500 participants will be enrolled and can expect to be on study for 12 months. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Smoking Cessation, Electronic Cigarette Use
- What is being tested?
- Varenicline, Nicotine patch and Dual Focused Cessation Counseling
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 1 siteUnited States
- Study dates
- 24 Sep 2024to Jul 2028
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Able to read and communicate in English
- Willing to set a quit date to quit smoking cigarettes in the next 30 days
- Willing and medically able to use varenicline and nicotine patches
- Smoking ≥ 5 cigarettes per day for the past 6 months
- Vaping weekly for at least 6 months
- Willing to stop using nicotine replacement or varenicline
Show all 11Show fewer
- Willing to stop using bupropion (i.e., Wellbutrin, Zyban) if they are currently using it only for smoking cessation
- Saliva cotinine >30 ng/ml
- US resident
- Own a Smartphone to use and download an app to record data
- have a working email so that they can receive links for video visits
Who cannot join
- Currently in treatment for psychosis or bipolar disorder
- If they are currently taking bupropion for non-smoking cessation reasons (e.g., Wellbutrin for depression)
- Currently pregnant or breastfeeding. If a participant becomes pregnant while in the study, they will be allowed to continue in the study but will no longer receive study medications. They will also be asked to return any unused study medications.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Wisconsin-Madison School of Medicine and Public Health
Madison, Wisconsin, 53792
Mark Zehner, 608-262-7568, mark.zehner@wisc.edu
Megan Piper, PhD
About this study
Official title: Dual Use Cessation: A MOST Screening Trial to Identify Effective Interventions to Help People Who Smoke and Vape
The overarching goal of this research is to determine the most effective approach for helping dual users of cigarettes and electronic nicotine delivery systems (ENDS) quit smoking. 500 participants will be enrolled and can expect to be on study for 12 months.
Read the detailed description
To be efficient and maximize translation potential, the investigators will use the efficient Multiphase Optimization Strategy (MOST) to identify an optimal intervention to help people who use both cigarettes and ENDS quit smoking cigarettes. As such, in this randomized 2x2x2 factorial screening trial, the investigators will examine three intervention components:
- Pharmacotherapy (varenicline vs. nicotine patch)
- Counseling Intensity (4 vs. 1 session)
- Counseling Approach (Dual Focused vs. Smoking Focused).
The Dual Focused counseling approach will encourage participants to quit their ENDS use as part of their smoking cessation attempt. The Smoking Focused counseling approach will encourage participants to quit smoking but not vaping and to use their ENDS strategically to deal with urges in service of harm reduction. There is theoretical and empirical support for these pharmacologic and counseling approaches and intensities.
Participants (N=500) will be dual users of cigarettes (>4 cigs/day for the last 6 months) and ENDS (vape weekly for at least 6 months) who are motivated to quit smoking and willing try to quit vaping, if asked to do so. Participants will be recruited, assessed, and treated remotely. They will be randomized to receive either varenicline or nicotine patches for 12 weeks, to receive either one or four 15-20-minute counseling sessions, and to receive counseling that is either dual focused or smoking focused. Dual Focused Cessation will focus on quitting both smoking and vaping on the target quit date (TQD). Pre-TQD, participants will be instructed to change smoking and vaping patterns (e.g., not smoking or vaping in specific places or at specific times of day). Post-TQD, participants will focus on building smoking and vaping cessation skills (e.g., coping with cravings to smoke or vape, avoiding smoking and vaping cues). Smoking Focused Cessation will focus on quitting smoking on the TQD and using ENDS as a behavioral substitute (i.e., using ENDS as a cigarette substitute). Pre-TQD, participants will be instructed to change smoking patterns (e.g., vaping rather than smoking in specific places or at specific times of day, vaping first in the morning rather than smoking) and practice smoking cessation coping strategies (e.g., substituting ENDS for cigarettes, avoiding smoking cues). Participants will be advised to quit smoking on the TQD and not worry about quitting vaping at this point. Participants will complete daily measures of smoking, vaping, and potential change mechanisms (e.g., craving, smoking reward, self-efficacy) via ecological momentary assessment (EMA) for 2 weeks pre-TQD and 2 weeks post-TQD. Follow-up will occur for 12 months post-TQD.
Primary Objective: Determine which pharmacologic and counseling approaches are especially effective, alone or in combination, in helping dual users quit smoking.
Secondary Objectives:
- Examine the effects of the treatments on variables that may mediate treatment effects on smoking cessation.
- Examine
- changes in vaping intensity and vaping cessation
- moderators of treatment effects (e.g., cigarette dependence, race, menthol use, ENDS characteristics), and
- whether continued vaping is related to cigarette lapse and relapse amongst those who have quit smoking.
- Conditions
- Smoking Cessation, Electronic Cigarette Use
- Being tested
- Varenicline, Nicotine patch, Dual Focused Cessation Counseling, Smoking Focused Cessation Counseling, Counseling Intensity: 1 Session
- Keywords
- ENDS, Cessation
- Medical subject headings
- Smoking Cessation, Vaping
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VareniclineDrug
0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (at least 8 hours apart) for 4 days prior to the TQD. On the 8th day (the TQD), participants will increase to their target maintenance dose of a 1 mg pill twice daily
Nicotine patchDrug
Following package inserts starting on the TQD, participants who smoke >10 cigarettes per day at baseline will be given 8 weeks of 21 mg nicotine patches, followed by 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Participants who smoke ≤10 cigarettes per day at baseline will be given 10 weeks of 14 mg nicotine patches followed by 2 weeks of 7 mg patches.
Dual Focused Cessation CounselingBehavioural
Dual Focused Cessation Counseling will focus on quitting both smoking and vaping. Specifically, participants will be instructed to change smoking and vaping patterns (e.g., not smoking or vaping in specific places such as the car or at specific times of day) prior to quitting and to practice cessation coping strategies (e.g., distraction techniques, getting social support).
Smoking Focused Cessation CounselingBehavioural
Smoking Focused Cessation Counseling will focus on quitting smoking and using ENDS as a harm reduction strategy (i.e., using ENDS as a substitute for cigarettes).
Counseling Intensity: 1 SessionOther
Participants assigned to one session will complete a single, 15-20 minute, session at Visit 2 (1 week pre-TQD).
Counseling Intensity: 4 SessionsOther
Participants assigned to intensive counseling will have four, 15-20-minute sessions.
| Study group | Role | What they receive |
|---|---|---|
| Varenicline, Dual Focused, 1 session | Active comparator | Not described Receives: Drug: Varenicline; Behavioral: Dual Focused Cessation Counseling; Other: Counseling Intensity: 1 Session |
| Varenicline, Dual Focused, 4 sessions | Active comparator | Not described Receives: Drug: Varenicline; Behavioral: Dual Focused Cessation Counseling; Other: Counseling Intensity: 4 Sessions |
| Varenicline, Smoking Focused, 1 session | Active comparator | Not described Receives: Drug: Varenicline; Behavioral: Smoking Focused Cessation Counseling; Other: Counseling Intensity: 1 Session |
| Varenicline, Smoking Focused, 4 sessions | Active comparator | Not described Receives: Drug: Varenicline; Behavioral: Smoking Focused Cessation Counseling; Other: Counseling Intensity: 4 Sessions |
| Nicotine Patches, Dual Focused, 1 session | Active comparator | Not described Receives: Drug: Nicotine patch; Behavioral: Dual Focused Cessation Counseling; Other: Counseling Intensity: 1 Session |
| Nicotine Patches, Dual Focused, 4 sessions | Active comparator | Not described Receives: Drug: Nicotine patch; Behavioral: Dual Focused Cessation Counseling; Other: Counseling Intensity: 4 Sessions |
| Nicotine Patches, Smoking Focused, 1 session | Active comparator | Not described Receives: Drug: Nicotine patch; Behavioral: Smoking Focused Cessation Counseling; Other: Counseling Intensity: 1 Session |
| Nicotine Patches, Smoking Focused, 4 sessions | Active comparator | Not described Receives: Drug: Nicotine patch; Behavioral: Smoking Focused Cessation Counseling; Other: Counseling Intensity: 4 Sessions |
What is being measured
The primary outcome is the main question the study is designed to answer.
52-week biochemically confirmed 7-day point-prevalence abstinence from cigarettes
52-week biochemically confirmed (anabasine<2 ng/ml) 7-day point-prevalence abstinence from cigarettes
Measured: up to 52 weeks
Secondary outcomes (2)
26-week biochemically confirmed 7-day point-prevalence abstinence from cigarettes
26-week biochemically confirmed (anabasine<2 ng/ml) 7-day point-prevalence abstinence from cigarettes
Measured: up to 26 weeks
7-day point-prevalence abstinence from smoking and vaping at Weeks 26 and 52 post-TQD
Biochemically confirmed with saliva cotinine <30 ng/mL
Measured: up to 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2024
- Study start24 Sep 2024
- Primary completionJul 2028 (estimated)
- Study completionJul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Smoking CessationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- 2x2x2 factorial screening trial
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Megan E Piper, PhD, Principal investigator, University of Wisconsin, Madison
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06474299
- Sponsor's protocol ID
- 2024-0019
- Other IDs
- R01CA290895, A534253, SMPH/MEDICINE/GEN INT MD, Protocol Version 9/4/2026
- Status last verified
- Oct 2026
- First submitted
- 19 Jun 2024
- Last updated
- 7 Oct 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dual Use Cessation: A MOST Screening Trial to Identify Effective Interventions to Help People Who Smoke and Vape
- ClinicalTrials.gov ID
- NCT06474299
- Acronym / sponsor ID
- 2024-0019
- Conditions
- Smoking Cessation, Electronic Cigarette Use
- Keywords
- ENDS, Cessation
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- University of Wisconsin, MadisonUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 24 Sep 2024 (actual)
- Primary completion
- Jul 2028 (estimated)
- Study completion
- Jul 2028 (estimated)
- First posted
- 25 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overarching goal of this research is to determine the most effective approach for helping dual users of cigarettes and electronic nicotine delivery systems (ENDS) quit smoking. 500 participants will be enrolled and can expect to be on study for 12 months.
Detailed description
To be efficient and maximize translation potential, the investigators will use the efficient Multiphase Optimization Strategy (MOST) to identify an optimal intervention to help people who use both cigarettes and ENDS quit smoking cigarettes. As such, in this randomized 2x2x2 factorial screening trial, the investigators will examine three intervention components:
- Pharmacotherapy (varenicline vs. nicotine patch)
- Counseling Intensity (4 vs. 1 session)
- Counseling Approach (Dual Focused vs. Smoking Focused).
The Dual Focused counseling approach will encourage participants to quit their ENDS use as part of their smoking cessation attempt. The Smoking Focused counseling approach will encourage participants to quit smoking but not vaping and to use their ENDS strategically to deal with urges in service of harm reduction. There is theoretical and empirical support for these pharmacologic and counseling approaches and intensities.
Participants (N=500) will be dual users of cigarettes (>4 cigs/day for the last 6 months) and ENDS (vape weekly for at least 6 months) who are motivated to quit smoking and willing try to quit vaping, if asked to do so. Participants will be recruited, assessed, and treated remotely. They will be randomized to receive either varenicline or nicotine patches for 12 weeks, to receive either one or four 15-20-minute counseling sessions, and to receive counseling that is either dual focused or smoking focused. Dual Focused Cessation will focus on quitting both smoking and vaping on the target quit date (TQD). Pre-TQD, participants will be instructed to change smoking and vaping patterns (e.g., not smoking or vaping in specific places or at specific times of day). Post-TQD, participants will focus on building smoking and vaping cessation skills (e.g., coping with cravings to smoke or vape, avoiding smoking and vaping cues). Smoking Focused Cessation will focus on quitting smoking on the TQD and using ENDS as a behavioral substitute (i.e., using ENDS as a cigarette substitute). Pre-TQD, participants will be instructed to change smoking patterns (e.g., vaping rather than smoking in specific places or at specific times of day, vaping first in the morning rather than smoking) and practice smoking cessation coping strategies (e.g., substituting ENDS for cigarettes, avoiding smoking cues). Participants will be advised to quit smoking on the TQD and not worry about quitting vaping at this point. Participants will complete daily measures of smoking, vaping, and potential change mechanisms (e.g., craving, smoking reward, self-efficacy) via ecological momentary assessment (EMA) for 2 weeks pre-TQD and 2 weeks post-TQD. Follow-up will occur for 12 months post-TQD.
Primary Objective: Determine which pharmacologic and counseling approaches are especially effective, alone or in combination, in helping dual users quit smoking.
Secondary Objectives:
- Examine the effects of the treatments on variables that may mediate treatment effects on smoking cessation.
- Examine
- changes in vaping intensity and vaping cessation
- moderators of treatment effects (e.g., cigarette dependence, race, menthol use, ENDS characteristics), and
- whether continued vaping is related to cigarette lapse and relapse amongst those who have quit smoking.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 8
- Model description
- 2x2x2 factorial screening trial
| Arm | Type | Receives |
|---|---|---|
| Varenicline, Dual Focused, 1 session | Active comparator | Drug: Varenicline, Behavioral: Dual Focused Cessation Counseling, Other: Counseling Intensity: 1 Session |
| Varenicline, Dual Focused, 4 sessions | Active comparator | Drug: Varenicline, Behavioral: Dual Focused Cessation Counseling, Other: Counseling Intensity: 4 Sessions |
| Varenicline, Smoking Focused, 1 session | Active comparator | Drug: Varenicline, Behavioral: Smoking Focused Cessation Counseling, Other: Counseling Intensity: 1 Session |
| Varenicline, Smoking Focused, 4 sessions | Active comparator | Drug: Varenicline, Behavioral: Smoking Focused Cessation Counseling, Other: Counseling Intensity: 4 Sessions |
| Nicotine Patches, Dual Focused, 1 session | Active comparator | Drug: Nicotine patch, Behavioral: Dual Focused Cessation Counseling, Other: Counseling Intensity: 1 Session |
| Nicotine Patches, Dual Focused, 4 sessions | Active comparator | Drug: Nicotine patch, Behavioral: Dual Focused Cessation Counseling, Other: Counseling Intensity: 4 Sessions |
| Nicotine Patches, Smoking Focused, 1 session | Active comparator | Drug: Nicotine patch, Behavioral: Smoking Focused Cessation Counseling, Other: Counseling Intensity: 1 Session |
| Nicotine Patches, Smoking Focused, 4 sessions | Active comparator | Drug: Nicotine patch, Behavioral: Smoking Focused Cessation Counseling, Other: Counseling Intensity: 4 Sessions |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Able to read and communicate in English
- Willing to set a quit date to quit smoking cigarettes in the next 30 days
- Willing and medically able to use varenicline and nicotine patches
- Smoking ≥ 5 cigarettes per day for the past 6 months
- Vaping weekly for at least 6 months
Key exclusion criteria (3 listed)
- Currently in treatment for psychosis or bipolar disorder
- If they are currently taking bupropion for non-smoking cessation reasons (e.g., Wellbutrin for depression)
- Currently pregnant or breastfeeding. If a participant becomes pregnant while in the study, they will be allowed to continue in the study but will no longer receive study medications. They will also be asked to return any unused study medications.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Varenicline0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (at least 8 hours apart) for 4 days prior to the TQD. On the 8th day (the TQD), participants will increase to their target maintenance dose of a 1 mg pill twice daily | Drug | Varenicline, Dual Focused, 1 session, Varenicline, Dual Focused, 4 sessions, Varenicline, Smoking Focused, 1 session, Varenicline, Smoking Focused, 4 sessions |
| Nicotine patchFollowing package inserts starting on the TQD, participants who smoke >10 cigarettes per day at baseline will be given 8 weeks of 21 mg nicotine patches, followed by 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Participants who smoke ≤10 cigarettes per day at baseline will be given 10 weeks of 14 mg nicotine patches followed by 2 weeks of 7 mg patches. | Drug | Nicotine Patches, Dual Focused, 1 session, Nicotine Patches, Dual Focused, 4 sessions, Nicotine Patches, Smoking Focused, 1 session, Nicotine Patches, Smoking Focused, 4 sessions |
| Dual Focused Cessation CounselingDual Focused Cessation Counseling will focus on quitting both smoking and vaping. Specifically, participants will be instructed to change smoking and vaping patterns (e.g., not smoking or vaping in specific places such as the car or at specific times of day) prior to quitting and to practice cessation coping strategies (e.g., distraction techniques, getting social support). | Behavioural | Nicotine Patches, Dual Focused, 1 session, Nicotine Patches, Dual Focused, 4 sessions, Varenicline, Dual Focused, 1 session, Varenicline, Dual Focused, 4 sessions |
| Smoking Focused Cessation CounselingSmoking Focused Cessation Counseling will focus on quitting smoking and using ENDS as a harm reduction strategy (i.e., using ENDS as a substitute for cigarettes). | Behavioural | Nicotine Patches, Smoking Focused, 1 session, Nicotine Patches, Smoking Focused, 4 sessions, Varenicline, Smoking Focused, 1 session, Varenicline, Smoking Focused, 4 sessions |
| Counseling Intensity: 1 SessionParticipants assigned to one session will complete a single, 15-20 minute, session at Visit 2 (1 week pre-TQD). | Other | Nicotine Patches, Dual Focused, 1 session, Nicotine Patches, Smoking Focused, 1 session, Varenicline, Dual Focused, 1 session, Varenicline, Smoking Focused, 1 session |
| Counseling Intensity: 4 SessionsParticipants assigned to intensive counseling will have four, 15-20-minute sessions. | Other | Nicotine Patches, Dual Focused, 4 sessions, Nicotine Patches, Smoking Focused, 4 sessions, Varenicline, Dual Focused, 4 sessions, Varenicline, Smoking Focused, 4 sessions |
Primary outcome
52-week biochemically confirmed 7-day point-prevalence abstinence from cigarettes
Time frame: up to 52 weeks
52-week biochemically confirmed (anabasine<2 ng/ml) 7-day point-prevalence abstinence from cigarettes
2 secondary outcomes
26-week biochemically confirmed 7-day point-prevalence abstinence from cigarettes
Time frame: up to 26 weeks
7-day point-prevalence abstinence from smoking and vaping at Weeks 26 and 52 post-TQD
Time frame: up to 52 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Individual participant dataSharing planned: Yes
Related trials for Smoking Cessation
Recruiting
Smoking Cessation in Patients With Cancer
Cancer, Tobacco Use
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
Not yet recruiting
Effectiveness Of Project EX: A Classroom-Based Smoking Prevention And Cessation Intervention Program
Focus of the Study is Smoking Cessation and Prevention, Smoking Prevention
RecruitingObservational study
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Chronic Obstructive Pulmonary Disease (COPD), Smoking
Recruiting
Therapeutic Contact Intensity in a Psychological Smoking Cessation Intervention With an App
Smoking Behaviors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Megan E Piper, PhD principal investigator
University of Wisconsin, Madison
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Varenicline, Nicotine patch and Dual Focused Cessation Counseling in people with Smoking Cessation and Electronic Cigarette Use, run by University of Wisconsin, Madison at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mark Zehner (608-262-7568, mark.zehner@wisc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
52-week biochemically confirmed 7-day point-prevalence abstinence from cigarettes (time frame: up to 52 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.